The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer

Published:2006-04-24 Issue:5 Volume:15 Page:507-517
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Miyake Hideaki¹,Hara Isao²,Fujisawa Masato²,Gleave Martin E³

Affiliation:

1. Hyogo Medical Center for Adults, Department of Urology, 13-70 Kitaohji-cho, Akashi 673-8558, Japan.

2. Kobe University School of Medicine, Department of Urology, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan

3. University of Brotish Columbia, Division of Urology, D-9, 2733 Heather Street, Vancouver V5Z 3J5, Canada

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1517/13543784.15.5.507

Reference113 articles.

1. Androgen Deprivation Therapy for Prostate Cancer

2. Prostate cancer update

3. LONG-TERM BIOCHEMICAL DISEASE-FREE AND CANCER-SPECIFIC SURVIVAL FOLLOWING ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY

4. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

5. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Clusterin in Carcinogenesis and its Potential Utility as Therapeutic Target;Current Medicinal Chemistry;2016-12-09

2. The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target;Expert Review of Anticancer Therapy;2015-08-26

3. Clusterin transcript variants expression in thyroid tumor: a potential marker of malignancy?;BMC Cancer;2015-05-02

4. Regulation of the expression of CLU isoforms in endometrial proliferative diseases;International Journal of Oncology;2013-04-11

5. Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel;Urologic Oncology: Seminars and Original Investigations;2012-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3